BusinessDaré Bioscience, Inc. announces Memorandum of Understanding with CONRAD for the conduct of the Ovaprene® postcoital test clinical trialBy Nasdaq OMXJul 24, 2017, 12:30 PM UTC
BusinessDaré Bioscience, Inc. trading on The NASDAQ Capital Market under the symbol “DARE”By Nasdaq OMXJul 20, 2017, 12:30 PM UTC
BusinessAgile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®By Nasdaq OMXJun 27, 2017, 12:00 PM UTC
BusinessAgile Therapeutics Reports First Quarter 2017 Financial ResultsBy Nasdaq OMXMay 8, 2017, 8:11 PM UTC
BusinessAgile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017By Nasdaq OMXMay 6, 2017, 6:05 PM UTC
BusinessAgile Therapeutics to Present Additional Phase 3 Data at the 2017 Annual Clinical and Scientific Meeting of the American Congress of Obstetricians and GynecologistsBy Nasdaq OMXMay 3, 2017, 8:15 PM UTC
BusinessAgile Therapeutics Announces Presentation of SECURE Phase 3 Data at the 2017 Congress on Women’s HealthBy Nasdaq OMXApr 27, 2017, 11:31 AM UTC
BusinessAgile Therapeutics Announces Results of its Pre-Submission Meeting with FDABy Nasdaq OMXApr 11, 2017, 11:00 AM UTC
